The company has delayed the FDA filing, but not the EMA filing. And rightly so: well before decision time, the EMA will have finalized its AD endpoint guidelines.
Our FDA delay is very likely to focus on the EMA, and then leverage that effort into the similar FDA submission. Could have been done simultaneously, but the company seems to want to take a more conservative approach. May have been partly due to resource constraints.
Market Data 
Markets 
AI
